The USPTO has announced a further delay of the fee for patent applications that are not filed in DOCX format. Originally set to take effect January 1, 2022, and then delayed to January 1, 2023, the USPTO now has delayed the effective date to April 3, 2023. This means applicants and legal teams returning from winter holiday vacations won’t be forced to file utility patent applications in DOCX format or pay an additional $400 (large entity), but will have a few more months to get comfortable with the DOCX filing and validation process.
As set forth in the Federal Register Notice, applicants are “strongly encouraged” to begin filing patent applications in DOCX format now, before the new fee takes effect. The USPTO has offered and continues to offer DOCX training sessions and other resources.
Disclaimer
This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.
Author(s)
Related Insights
June 1, 2026
PharmaPatents
New USPTO “Pre-Docketing Notice” Pilot Program Could Streamline Examination
The USPTO announced a new pilot program that could streamline examination, improve examination efficiency, and help the USPTO use its examination resources more efficiently. The “Pre-Docketing Notice” pilot program also offers significant benefits to patent applicants, providing a timely opportunity to trim portfolios to save costs or align portfolios with current commercial objectives, which may have shifted in the years since the patent application was filed.
May 6, 2026
PharmaPatents
Flexibility Versus Indefiniteness: What It’s All About
In Enviro Tech Chemical Servs., Inc. v. Safe Foods Corp., the Federal Circuit recognized the permissibility of using “about” to “avoid a strict numerical boundary” for a claimed parameter, but held the claims at issue invalid as indefinite under 35 U.S.C. § 112(b). The court’s analysis highlights that the flexibility of “about” comes with a risk of invalidity, especially when the scope of the claimed range cannot be ascertained from the specification and prosecution history with reasonable certainty.
April 9, 2026
PharmaPatents
USPTO to Take a Piercing Look at National Stage Applications
USPTO’s PIER pilot program adds a new “confirm‑to‑proceed” step for selected U.S. national stage applications. The PIER program may increase costs, cause delays, and reduce patent term adjustment (PTA). The USPTO may benefit by reducing its workload without refunding examination fees.